These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30369613)

  • 1. Effect of Zinc Acetate Dihydrate (NobelzinR) Treatment on Anemia and Taste Disorders in Patients with Chronic Kidney Disease with Hypozincemia.
    Sato D; Gohda T; Kihara M; Kanaguchi Y; Kobayashi T; Mano S; Sasaki Y; Nohara N; Murakoshi M; Nakata J; Suzuki H; Ueda S; Horikoshi S; Suzuki Y
    Acta Med Okayama; 2018 Oct; 72(5):535-538. PubMed ID: 30369613
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The role of zinc in chronic kidney disease].
    Fukushima T
    Nihon Rinsho; 2016 Jul; 74(7):1138-43. PubMed ID: 27455803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of Zinc Acetate Hydrate Supplementation on Renal Anemia with Hypozincemia in Hemodialysis Patients.
    Sato E; Sato S; Degawa M; Ono T; Lu H; Matsumura D; Nomura M; Moriyama N; Amaha M; Nakamura T
    Toxins (Basel); 2022 Oct; 14(11):. PubMed ID: 36355996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of zinc acetate hydrate and polaprezinc for zinc deficiency in patients on maintenance hemodialysis: A single-center, open-label, prospective randomized study.
    Okamoto T; Hatakeyama S; Konishi S; Okita K; Tanaka Y; Imanishi K; Takashima T; Saitoh F; Suzuki T; Ohyama C
    Ther Apher Dial; 2020 Oct; 24(5):568-577. PubMed ID: 31794152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-marketing surveillance of zinc acetate dihydrate for hypozincemia in Japan.
    Ezoe S; Ishihara T; Hosogai T; Kokubo T
    Pharmazie; 2024 Feb; 79(1):29-34. PubMed ID: 38509625
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (GSK1278863) for Anemia in CKD: A 28-Day, Phase 2A Randomized Trial.
    Brigandi RA; Johnson B; Oei C; Westerman M; Olbina G; de Zoysa J; Roger SD; Sahay M; Cross N; McMahon L; Guptha V; Smolyarchuk EA; Singh N; Russ SF; Kumar S;
    Am J Kidney Dis; 2016 Jun; 67(6):861-71. PubMed ID: 26827289
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Zinc deficiency anemia and effects of zinc therapy in maintenance hemodialysis patients.
    Fukushima T; Horike H; Fujiki S; Kitada S; Sasaki T; Kashihara N
    Ther Apher Dial; 2009 Jun; 13(3):213-9. PubMed ID: 19527468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevalence of anemia in predialysis chronic kidney disease patients.
    Shaheen FA; Souqiyyeh MZ; Al-Attar BA; Karkar A; Al Jazairi AM; Badawi LS; Ballut OM; Hakami AH; Naguib M; Al-Homrany MA; Barhamein MY; Ahmed AM; Khardaji MM; Said SA;
    Saudi J Kidney Dis Transpl; 2011 May; 22(3):456-63. PubMed ID: 21566300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravenous Versus Oral Iron Supplementation for the Treatment of Anemia in CKD: An Updated Systematic Review and Meta-analysis.
    Shepshelovich D; Rozen-Zvi B; Avni T; Gafter U; Gafter-Gvili A
    Am J Kidney Dis; 2016 Nov; 68(5):677-690. PubMed ID: 27321965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Zinc Supplementation on Nutritional Status in Children with Chronic Kidney Disease: A Randomized Trial.
    Escobedo-Monge MF; Ayala-Macedo G; Sakihara G; Peralta S; Almaraz-Gómez A; Barrado E; Marugán-Miguelsanz JM
    Nutrients; 2019 Nov; 11(11):. PubMed ID: 31694220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Zinc deficiency and taste disorders.
    Heyneman CA
    Ann Pharmacother; 1996 Feb; 30(2):186-7. PubMed ID: 8835055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Long-acting erythropoetin efficacy in the treatment of nephrogenic anemia in patients with chronic kidney disease during predialysis stage].
    Milovanov IuS; Milovanova LIu
    Ter Arkh; 2012; 84(6):48-52. PubMed ID: 22997919
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of uremic hypogeusia by zinc: a double-blind study.
    Mahajan SK; Prasad AS; Lambujon J; Abbasi AA; Briggs WA; McDonald FD
    Am J Clin Nutr; 1980 Jul; 33(7):1517-21. PubMed ID: 6772011
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 2008 Japanese Society for Dialysis Therapy: guidelines for renal anemia in chronic kidney disease.
    Tsubakihara Y; Nishi S; Akiba T; Hirakata H; Iseki K; Kubota M; Kuriyama S; Komatsu Y; Suzuki M; Nakai S; Hattori M; Babazono T; Hiramatsu M; Yamamoto H; Bessho M; Akizawa T
    Ther Apher Dial; 2010 Jun; 14(3):240-75. PubMed ID: 20609178
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Do we successfully treat anemia and calcium-phosphate disorders in children with chronic kidney disease at the beginning of the twenty-first century?].
    Drożdż D; Kwinta P; Sztefko K; Zachwieja K; Miklaszewska M; Drożdż T; Łatka M; Pietrzyk JA
    Przegl Lek; 2015; 72(7):349-53. PubMed ID: 26817347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zinc supplementation and its effect on taste acuity in children with chronic renal failure.
    Watson AR; Stuart A; Wells FE; Houston IB; Addison GM
    Hum Nutr Clin Nutr; 1983 May; 37(3):219-25. PubMed ID: 6347985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
    Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
    BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral zinc supplementation reduces the erythropoietin responsiveness index in patients on hemodialysis.
    Kobayashi H; Abe M; Okada K; Tei R; Maruyama N; Kikuchi F; Higuchi T; Soma M
    Nutrients; 2015 May; 7(5):3783-95. PubMed ID: 25988769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia.
    Locatelli F; Mandolfo S; Menegato Adorati M; Villa G; Tarchini R; Pizzarelli F; Conte F; Guastoni C; Ricciardi B; Crotta A
    J Nephrol; 2013; 26(6):1114-21. PubMed ID: 24052462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale and study design of a randomized controlled trial to assess the effects of maintaining hemoglobin levels using darbepoetin alfa on prevention of development of end-stage kidney disease in non-diabetic CKD patients (PREDICT Trial).
    Imai E; Maruyama S; Nangaku M; Hirakata H; Hayashi T; Narita I; Kono H; Nakatani E; Morita S; Tsubakihara Y; Akizawa T
    Clin Exp Nephrol; 2016 Feb; 20(1):71-6. PubMed ID: 26081567
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.